Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics

Trillium Therapeutics Inc. (TRIL)

Today's Latest Price: $8.91 USD

0.57 (6.83%)

Updated Aug 13 5:56pm

Add TRIL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TRIL Daily Price Range
TRIL 52-Week Price Range

TRIL Stock Price Chart Technical Analysis Charts

TRIL Price/Volume Stats

Current price $8.91 52-week high $9.66
Prev. close $8.34 52-week low $0.24
Day low $8.29 Volume 921,669
Day high $8.91 Avg. volume 3,182,183
50-day MA $7.81 Dividend yield N/A
200-day MA $4.40 Market Cap 753.57M

Trillium Therapeutics Inc. (TRIL) Company Bio

Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.

TRIL Latest News Stream

Event/Time News Detail
Loading, please wait...

TRIL Latest Social Stream

Loading social stream, please wait...

View Full TRIL Social Stream

Latest TRIL News From Around the Web

Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.

Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, provided an update today on its ongoing phase 1b dose optimization study of TTI-621 in patients with relapsed and/or refractory cutaneous T-cell lymphoma (CTCL). TTI-621 is an innate immune checkpoint inhibitor targeting CD47, a “don’t eat me” signal that cancer cells use to evade destruction by the immune system. “We are pleased to report that we have successfully completed the safety assessment part of the 1.4 mg/kg cohort, with no DLTs observed,” said Jan Skvarka, President and Chief Executive Officer of Trillium. “After experiencing a temporary slow-down i...

Yahoo | July 30, 2020

Is the Options Market Predicting a Spike in Trillium Therapeutics (TRIL) Stock?

Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.

Yahoo | July 20, 2020

Did Hedge Funds Make The Right Call On Trillium Therapeutics Inc. (TRIL) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 18, 2020

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

CAMBRIDGE, Mass., July 06, 2020 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies.

Yahoo | July 6, 2020

The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announc...

Benzinga | June 23, 2020

Read More 'TRIL' Stories Here

TRIL Price Returns

1-mo 21.06%
3-mo 52.83%
6-mo 159.01%
1-year 3,513.14%
3-year 113.41%
5-year -53.69%
YTD 765.05%
2019 -39.77%
2018 -76.41%
2017 28.32%
2016 -55.19%
2015 40.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7578 seconds.